1,5-anhydroglucitol has been researched along with dapagliflozin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glodzik, W; Hohendorff, J; Kapusta, M; Kiec-Wilk, B; Klupa, T; Ludwig-Galezowska, A; Malecki, MT; Mrozinska, S; Parpan, T; Platek, T; Skupien, J; Szopa, M; Zapala, B | 1 |
1 other study(ies) available for 1,5-anhydroglucitol and dapagliflozin
| Article | Year |
|---|---|
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Creatinine; Deoxyglucose; Diabetes Mellitus, Type 2; Female; Glucokinase; Glucosides; Glycosuria; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Male; Middle Aged; Mutation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2017 |